FGFR2 (E565G)
Sign in to save this workspaceFGFR2 · Variant type: point · HGVS: p.E565G
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Futibatinib | 99.7% | 0.3% | 98.48 |
| 2 | Vandetanib | 99.7% | 0.3% | 95.74 |
| 3 | Ponatinib | 98.8% | 1.2% | 78.23 |
| 4 | Selpercatinib | 98.6% | 1.4% | 96.72 |
| 5 | Canertinib | 98.3% | 1.7% | 96.49 |
| 6 | Alpelisib | 98.0% | 2.0% | 97.22 |
| 7 | Lenvatinib | 97.8% | 2.2% | 97.74 |
| 8 | Brigatinib | 97.6% | 2.4% | 82.96 |
| 9 | Infigratinib | 97.5% | 2.5% | 98.24 |
| 10 | Pazopanib | 97.4% | 2.6% | 97.49 |
| 11 | Erdafitinib | 97.0% | 3.0% | 95.71 |
| 12 | Dacomitinib | 96.7% | 3.3% | 97.99 |
| 13 | Pemigatinib | 96.6% | 3.4% | 98.23 |
| 14 | Erlotinib | 96.5% | 3.5% | 99.75 |
| 15 | Nintedanib | 96.0% | 4.0% | 90.23 |
| 16 | Axitinib | 91.5% | 8.5% | 93.23 |
| 17 | Pralsetinib | 90.3% | 9.7% | 93.43 |
| 18 | Tivozanib | 89.0% | 11.0% | 92.42 |
| 19 | Sunitinib | 88.2% | 11.8% | 91.73 |
| 20 | Fedratinib | 84.9% | 15.1% | 96.21 |
| 21 | Tenalisib | 83.9% | 16.1% | 97.98 |
| 22 | Gefitinib | 83.5% | 16.5% | 99.25 |
| 23 | Pexidartinib | 82.0% | 18.0% | 99.49 |
| 24 | Repotrectinib | 80.5% | 19.5% | 84.21 |
| 25 | Bosutinib | 76.3% | 23.7% | 87.22 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Futibatinib | 99.7% | 99.3% | +0.4% |
| Vandetanib | 99.7% | 90.8% | +8.8% |
| Ponatinib | 98.8% | 99.4% | -0.6% |
| Selpercatinib | 98.6% | 95.0% | +3.6% |
| Canertinib | 98.3% | — | — |
| Alpelisib | 98.0% | 98.9% | -1.0% |
| Lenvatinib | 97.8% | 85.4% | +12.5% |
| Brigatinib | 97.6% | 96.1% | +1.5% |
| Infigratinib | 97.5% | 98.8% | -1.3% |
| Pazopanib | 97.4% | 88.9% | +8.5% |
| Erdafitinib | 97.0% | 99.0% | -2.0% |
| Dacomitinib | 96.7% | — | — |
| Pemigatinib | 96.6% | 98.7% | -2.2% |
| Erlotinib | 96.5% | — | — |
| Nintedanib | 96.0% | 97.0% | -1.0% |
| Axitinib | 91.5% | 96.1% | -4.6% |
| Pralsetinib | 90.3% | 93.2% | -2.9% |
| Tivozanib | 89.0% | — | — |
| Sunitinib | 88.2% | — | — |
| Fedratinib | 84.9% | — | — |
| Tenalisib | 83.9% | 96.0% | -12.1% |
| Gefitinib | 83.5% | — | — |
| Pexidartinib | 82.0% | — | — |
| Repotrectinib | 80.5% | 79.8% | +0.7% |
| Bosutinib | 76.3% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| endometrial_carcinoma | Uterus | ref |
| carcinoma_liver | Liver | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.1ms